coagulants

Summary

Summary: Exogenous substances used to promote blood coagulation. The endogenous BLOOD COAGULATION FACTORS are considered to be coagulants only when administered as drugs.

Top Publications

  1. ncbi Recombinant human activated factor VII is thrombogenic in a rabbit model of cyclic flow reduction and does not reduce intra-abdominal bleeding
    Sonia Charbonneau
    Department of Anesthesiology, CHUM, Hopital Notre Dame, Montreal, Canada
    Thromb Haemost 97:296-303. 2007
  2. ncbi Rare inherited disorders of fibrinogen
    S S Acharya
    Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10021, USA
    Haemophilia 14:1151-8. 2008
  3. ncbi Perfusion-based microfluidic device for three-dimensional dynamic primary human hepatocyte cell culture in the absence of biological or synthetic matrices or coagulants
    Vasiliy N Goral
    Science and Technology, Corning Incorporated, Corning, New York 14831 0001, USA
    Lab Chip 10:3380-6. 2010
  4. pmc Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs
    Jennifer A Dumont
    Research and Development, Biogen Idec Hemophilia, Waltham, MA 02451, USA
    Blood 119:3024-30. 2012
  5. ncbi Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens
    P W Collins
    University Hospital of Wales, Arthur Bloom Hemophilia centre, Cardiff, Wales, UK
    J Thromb Haemost 8:269-75. 2010
  6. ncbi Recombinant clotting factors
    Steven W Pipe
    Department of Pediatrics and Communicable Diseases, University of Michigan, L2110 Women s Hospital, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Thromb Haemost 99:840-50. 2008
  7. ncbi Biochemistry and genetics of von Willebrand factor
    J E Sadler
    Howard Hughes Medical Institute, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri 63110, USA
    Annu Rev Biochem 67:395-424. 1998
  8. ncbi Store-mediated calcium entry in the regulation of phosphatidylserine exposure in blood cells from Scott patients
    Imke C A Munnix
    Department of Biochemistry, CARIM, Maastricht University, P O Box 616, 6200 MD Maastricht, The Netherlands
    Thromb Haemost 89:687-95. 2003
  9. ncbi Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices
    Michael T Ganter
    Department of Anesthesia and Perioperative Care, University of CA San Francisco, San Francisco, California, USA
    Anesth Analg 106:1366-75. 2008
  10. ncbi The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution
    Thorsten Haas
    Department of Anaesthesiology and Critical Care Medicine, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    Anesth Analg 106:1360-5, table of contents. 2008

Detail Information

Publications268 found, 100 shown here

  1. ncbi Recombinant human activated factor VII is thrombogenic in a rabbit model of cyclic flow reduction and does not reduce intra-abdominal bleeding
    Sonia Charbonneau
    Department of Anesthesiology, CHUM, Hopital Notre Dame, Montreal, Canada
    Thromb Haemost 97:296-303. 2007
    ..rHuFVIIa increases thrombosis in a rabbit model of carotid artery injury. The bleeding from hepatic and splenic lesions is not reduced by administration of rHuFVIIa despite a hypercoagulable state confirmed by standard TEG analysis...
  2. ncbi Rare inherited disorders of fibrinogen
    S S Acharya
    Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10021, USA
    Haemophilia 14:1151-8. 2008
    ..Rare Bleeding Disorder Registries developed through the United States and international efforts hopefully will encourage development and licensure of safer, effective products...
  3. ncbi Perfusion-based microfluidic device for three-dimensional dynamic primary human hepatocyte cell culture in the absence of biological or synthetic matrices or coagulants
    Vasiliy N Goral
    Science and Technology, Corning Incorporated, Corning, New York 14831 0001, USA
    Lab Chip 10:3380-6. 2010
    ..polarity and hepatocyte transport function in vitro without the addition of biological or synthetic matrices or coagulants. A unique feature of our dynamic cell culture device is the creation of a microenvironment, without the addition ..
  4. pmc Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs
    Jennifer A Dumont
    Research and Development, Biogen Idec Hemophilia, Waltham, MA 02451, USA
    Blood 119:3024-30. 2012
    ..5- to 2-fold longer than rFVIII. rFVIIIFc was well tolerated in both species. Thus, the rescue of FVIII by Fc fusion to provide prolonged protection presents a novel pathway for FVIII catabolism, and warrants further investigation...
  5. ncbi Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens
    P W Collins
    University Hospital of Wales, Arthur Bloom Hemophilia centre, Cardiff, Wales, UK
    J Thromb Haemost 8:269-75. 2010
    ..Prophylactic factor (F)VIII has been shown to reduce bleeds and arthropathy in patients with severe hemophilia A...
  6. ncbi Recombinant clotting factors
    Steven W Pipe
    Department of Pediatrics and Communicable Diseases, University of Michigan, L2110 Women s Hospital, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Thromb Haemost 99:840-50. 2008
    ..In turn, the ongoing development of new recombinant clotting factor concentrates is providing alternatives for patients with other inherited bleeding disorders...
  7. ncbi Biochemistry and genetics of von Willebrand factor
    J E Sadler
    Howard Hughes Medical Institute, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri 63110, USA
    Annu Rev Biochem 67:395-424. 1998
    ....
  8. ncbi Store-mediated calcium entry in the regulation of phosphatidylserine exposure in blood cells from Scott patients
    Imke C A Munnix
    Department of Biochemistry, CARIM, Maastricht University, P O Box 616, 6200 MD Maastricht, The Netherlands
    Thromb Haemost 89:687-95. 2003
    ..patient V.W. is a new case of Scott syndrome, ii. Ca(2+) entry in the platelets and lymphoblasts from both Scott patients is normal, and iii. elevated [Ca(2+)](i) as caused by SMCE is not sufficient to trigger PS exposure...
  9. ncbi Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices
    Michael T Ganter
    Department of Anesthesia and Perioperative Care, University of CA San Francisco, San Francisco, California, USA
    Anesth Analg 106:1366-75. 2008
    ..To ensure optimal accuracy and performance, standardized procedures for blood sampling and handling, strict quality controls and trained personnel are required...
  10. ncbi The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution
    Thorsten Haas
    Department of Anaesthesiology and Critical Care Medicine, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    Anesth Analg 106:1360-5, table of contents. 2008
    ....
  11. ncbi Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria
    H Pollmann
    Institut für Thrombophilie und Hämostaseologie, Munster, Germany
    Haemophilia 13:131-43. 2007
    ..These results emphasize the benefit of postmarketing surveillance and, overall, this study confirms the efficacy, safety and tolerability of REFACTO in the treatment of patients with haemophilia A...
  12. ncbi Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haemat
    D Keeling
    Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Oxford
    Haemophilia 14:671-84. 2008
    ..They include details of therapeutic products available in the UK and they update and replace previous United Kingdom Haemophilia Centre Doctors' Organisation guidelines...
  13. ncbi Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia
    A D Shapiro
    Indiana Hemophilia and Thrombosis Center, Inc, Indianapolis, IN 46260, USA
    Haemophilia 11:571-82. 2005
    ..We highlight the importance of considering an individual pharmacokinetic study in all patients starting a new coagulation product...
  14. ncbi Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention
    M E Mancuso
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, University of Milan, Milan, Italy
    Haemophilia 15:8-14. 2009
    ..Practical approaches to early prophylaxis as implemented in the haemophilia centres in Milan and Bremen are discussed in this respect...
  15. ncbi Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study
    Rosemarie Schobess
    Department of Pediatrics, University Hospital Halle, Halle, Germany
    Thromb Haemost 99:71-6. 2008
    ..77). No conclusion can be drawn from the data presented herein whether primary prophylaxis or an early start of secondary prophylaxis is superior with respect to joint outcome in children with severe HA...
  16. ncbi Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A
    N Risebrough
    HOPE Research Centre, Division of Clinical Pharmacology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada
    Haemophilia 14:743-52. 2008
    ..In conclusion, prophylaxis will substantially improve clinical outcomes and quality of life compared to Demand treatment, but with substantial cost...
  17. ncbi Massive, fatal, intracardiac thrombosis associated with prothrombin complex concentrate
    Otis Warren
    Department of Emergency Medicine, Alameda County Medical Center, Oakland, CA 94612, USA
    Ann Emerg Med 53:758-61. 2009
    ..Thrombogenic complications of treatment with prothrombin complex concentrate have been reported before. Caution should be used when using prothrombin complex concentrates for reversal of anticoagulation...
  18. ncbi Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A
    Sven Björkman
    Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE 751 24, Uppsala, Sweden
    Eur J Clin Pharmacol 65:989-98. 2009
    ....
  19. doi Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis
    Ingrid E M den Uijl
    Thromb Haemost 99:965; author reply 966-8. 2008
  20. ncbi Evidence for the benefits of prophylaxis in the management of hemophilia A
    W Keith Hoots
    Department of Pediatrics and Internal Medicine, University of Texas Medical School, Houston, Texas, USA
    Thromb Haemost 96:433-40. 2006
    ....
  21. ncbi Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development
    C Escuriola Ettingshausen
    Centre of Paediatrics III, Department of Haematology, Oncology and Haemostaseology, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany
    Haemophilia 12:102-6. 2006
    ..However, in order to provide more evidence a well-designed randomized study is needed...
  22. ncbi Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors
    J Astermark
    Department for Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 13:38-45. 2007
    ..General recommendations were developed, based on the information provided by the survey. The results clearly indicate the need for well-designed comparative studies to optimize the use of by-passing agents...
  23. ncbi Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
    G L Salvagno
    Department of Clinical Chemistry, Verona University Hospital, Verona, Italy
    Haemophilia 13:51-6. 2007
    ..The VWF-containing concentrates Fanhdi and Haemate-P, added to FVIII-deficient plasma with the presence of inhibitor, generate more thrombin than do the purified concentrates Hemofil-M and Kogenate Bayer...
  24. ncbi Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist
    M Kjalke
    Haemostasis Biology, Novo Nordisk A S, Måløv, Denmark
    J Thromb Haemost 5:774-80. 2007
    ..Activation of platelets with a combination of collagen and thrombin generates a subpopulation of highly procoagulant 'coated' platelets characterized by high surface expression of fibrinogen and other procoagulant proteins...
  25. ncbi Rapid reversal of anticoagulant bleeding- rFVIIa an option?
    Silva Zupancic-Salek
    J Postgrad Med 53:3-4. 2007
  26. ncbi Factor VIIa: mounting evidence or anecdotal reports
    R MacLaren
    J Postgrad Med 53:4-5. 2007
  27. ncbi Use of recombinant factor VIIa for emergency reversal of anticoagulation
    J Ingerslev
    Centre for Hemophilia and Thrombosis, University Hospital Skejby, Denmark
    J Postgrad Med 53:17-22. 2007
    ..There is limited data regarding the use of activated recombinant factor VII (rFVIIa) in anticoagulated patients requiring reversal...
  28. ncbi Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas
    Virginie B Louvain-Quintard
    INSERM U428, Faculte de Pharmacie, Universite Paris V, 75270 Paris, France
    J Biol Chem 280:41352-9. 2005
    ..It is also reasonable to expect little or no immunogenicity, because FX and fibrinopeptide A both circulate normally in the blood of hemophiliacs...
  29. ncbi Prophylaxis in haemophilia patients with inhibitors
    C A Leissinger
    Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA
    Haemophilia 12:67-72; discussion 72-3. 2006
    ..This article will review the published data on the use of bypassing agents in the prevention of bleeding, and will discuss ongoing clinical prophylaxis trials in inhibitor patients...
  30. ncbi Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics
    E Berntorp
    Malmö Center for Thrombosis and Hemostasis, Malmo University Hospital, Malmo, Sweden
    Haemophilia 12:62-5; discussion 65-6. 2006
    ..Antifibrinolytics are often administered as an adjunct therapy to the treatment protocol and have also been reported to have a direct anti-inhibitor effect...
  31. pmc The tissue factor requirement in blood coagulation
    Thomas Orfeo
    Department of Biochemistry, University of Vermont, Burlington, Vermont 05405, USA
    J Biol Chem 280:42887-96. 2005
    ..These observations support the hypothesis that the transient, localized expression of TF is sufficient to sustain a TF-independent procoagulant response as long as flow persists...
  32. ncbi Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy
    R F Johansen
    Department of Biochemistry, Centre for Haemophilia and Thrombosis, Aarhus University Hospital, Aarhus, Skejby, Denmark
    Haemophilia 12:190-7. 2006
    ..However, it seems that WB clotting profile studies at baseline, with ex vivo addition of haemostasis promoting agents, and during treatment may hold the potential to predict the success of treatment...
  33. ncbi Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery
    Conrad V Bishop
    Department of Cardiothoracic Surgery, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
    Ann Thorac Surg 81:875-9. 2006
    ....
  34. ncbi Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP)
    Tongyao Liu
    Avigen, Inc, 1301 Harbor Bay Pkwy, Alameda, CA 94502, USA
    Thromb Haemost 95:68-76. 2006
    ..Accordingly, administration of select NASP(s), via mechanism(s) not fully understood, represents a unique means of improving coagulation in bleeding disorders...
  35. ncbi Current issues in prophylactic therapy for persons with hemophilia
    Amy L Dunn
    Aflac Cancer Center and Blood Disorders Service, Department of Pediatrics, Emory University and Children s Healthcare of Atlanta, Atlanta, GA 30322, USA
    Acta Haematol 115:162-71. 2006
    ..Individualized treatment is recommended. Collaborative efforts are needed to improve outcomes for all persons with hemophilia...
  36. ncbi Surgery in patients with hemophilia and inhibitors: a review of the Norwegian experience with FEIBA
    Geir E Tjønnfjord
    Medical Department, Division of Hematology, Rikshospitalet Radiumhospitalet University Hospital, University of Oslo, Oslo, Norway
    Semin Hematol 43:S18-21. 2006
    ..He continued on FEIBA therapy and was stabilized with nitrates, opioid analgesia, and diuretics without clinical signs of heart failure...
  37. ncbi Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin
    William E Dager
    Department of Pharmaceutical Services, University of California, Davis Medical Center, Sacramento, California 95817 2201, USA
    Pharmacotherapy 26:1091-8. 2006
    ..To assess the effectiveness of using low-dose recombinant activated factor VII (rFVIIa) to reverse the effects of warfarin in critically ill patients with major bleeding events...
  38. ncbi Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays
    K P Radtke
    Bayer HealthCare, Biological Products, Research Triangle Park, NC, USA
    J Thromb Haemost 5:102-8. 2007
    ....
  39. ncbi ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A
    J Di Paola
    University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
    Haemophilia 13:124-30. 2007
    ..Results from this PKs comparison of two different rFVIII products, using chromogenic substrate assay to measure FVIII:C, showed that ReFacto and Advate are bioequivalent to each other...
  40. ncbi A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation
    B V Bysted
    Clinical Pharmacology, BIOPHARM, Novo Nordisk A S, Krogshøjvej 53A, DK 2880 Bagsvaerd, Denmark
    Haemophilia 13:527-32. 2007
    ..VII25's 'user-friendly' formulation removes the inconvenience of storing/transporting at 2-8 degrees C, and as the drug substance is the same, the activity and safety established for rFVIIa is maintained...
  41. ncbi Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting
    Roberto Musso
    Azienda Ospedale Vittorio Emanuele, Ospedale Ferrarotto, Catania, Italy
    Thromb Haemost 99:52-8. 2008
    ..Furthermore, these findings are consistent with those of previous phase III clinical studies with rFVIII-FS, particularly with regard to its efficacy and low incidence of inhibitor formation...
  42. doi Recombinant factor VIIa in massive obstetric haemorrhage
    N Bhuskute
    Eur J Anaesthesiol 25:250-1. 2008
  43. ncbi Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma
    Fania Szlam
    Department of Anesthesiology, Emory University School of Medicine, 1364 Clifton Rd, NE, Atlanta, GA 30322, USA
    Anesth Analg 106:719-24, table of contents. 2008
    ..We hypothesize that reduced AT concentrations would increase the procoagulant effects of rFVIIa in FVIII-deficient plasma...
  44. ncbi Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders
    Katherine F Croom
    Wolters Kluwer Health Adis, Auckland, New Zealand
    BioDrugs 22:121-36. 2008
    ..Cost data from pharmacoeconomic analyses support its use in hemophilia patients with inhibitors. Thus, recombinant factor VIIa is a valuable treatment option for patients with these rare, but potentially serious, bleeding disorders...
  45. ncbi Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice
    K Ovlisen
    Novo Nordisk A S, Måløv, Denmark
    J Thromb Haemost 6:969-75. 2008
    ..These result in hemophilic synovitis, an inflammatory and proliferative condition of the joint, which progresses into a chronic degenerative arthritis, hemophilic arthropathy...
  46. doi Factor VIIa gets even bigger
    William P Sheffield
    Thromb Haemost 99:653-4. 2008
  47. ncbi Prolonged in-vivo half-life of factor VIIa by fusion to albumin
    Thomas Weimer
    CSL Behring GmbH, Emil von Behring Strasse 76, 35041 Marburg, Germany
    Thromb Haemost 99:659-67. 2008
    ..The results of this study demonstrate that it is feasible to develop a half-life extended FVIIa molecule with haemostatic properties very similar to the wild-type factor...
  48. ncbi Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters
    Maria Elisa Mancuso
    Department of Medicine and Medical Specialities, Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation and University of Milan, Milan, Italy
    Br J Haematol 141:689-95. 2008
    ..This study showed that ports improved the feasibility of prophylaxis in the majority of non-inhibitor children, while they were not suitable for inhibitor children who require a prolonged ITI regimen with daily infusions...
  49. ncbi Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A
    James E Frampton
    Wolters Kluwer Health Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 68:839-53. 2008
    ..Available data indicate that sucrose-formulated octocog alfa is an appropriate alternative to other recombinant FVIII products for the treatment and prophylaxis of bleeding episodes in adults and children with haemophilia A...
  50. ncbi VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice
    E Berntorp
    Malmö Centre for Thrombosis and Haemostasis, Malmo University Hospital, Malmo, Sweden
    Haemophilia 13:69-72. 2007
    ..However, the clinical implications of all these findings in vitro need to be established...
  51. ncbi Inhibitors in haemophilia A: current management and open issues
    S Haya
    Unidad de Coagulopatías Congénitas, Hospital Universitario La Fe, Valencia, Spain
    Haemophilia 13:52-60. 2007
    ....
  52. pmc Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients
    Heng Joo Ng
    Department of Haematology, Singapore General Hospital, Singapore
    Vasc Health Risk Manag 2:433-40. 2006
    ..rFVIIa has been a remarkably safe agent for hemophiliacs but with high dosages being advocated and older patients being given such doses outside a trial setting, thromboembolic events remain a concern...
  53. ncbi Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A
    Benny Sørensen
    Centre for Haemophilia and Thrombosis, Aarhus University Hospital, Skejby, Aarhus N, Denmark
    Br J Haematol 137:158-65. 2007
    ..Altogether, these in vitro studies on WB revealed a favourable haemostatic potential of NN1731 compared with rFVIIa in severe haemophilia A, both in the absence and presence of enhanced fibrinolytic activity...
  54. ncbi Haemophilia therapies
    Yesim Dargaud
    Hopital Edouard Herriot, Comprehensive Haemophilia Treatment Centre, Lyon, France
    Expert Opin Biol Ther 7:651-63. 2007
    ....
  55. ncbi Recombinant factor VIIa should be used in massive obstetric haemorrhage
    Felicity Plaat
    Queen Charlotte s Hospital, London, UK
    Int J Obstet Anesth 16:354-7. 2007
  56. ncbi Recombinant factor VIIa should be used in massive obstetric haemorrhage
    M van de Velde
    Department of Anaesthesiology, Katholieke Universiteit Leuven and University Hospitals Gasthuisberg, Leuven, Belgium
    Int J Obstet Anesth 16:357-9. 2007
  57. ncbi Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres
    M Morfini
    Agency for Hemophilia, Azienda Ospedaliero Universitaria Careggi, Viale G B Morgagni No 85, I 50134 Florence, Italy
    Haemophilia 13:502-7. 2007
    ..Randomised controlled trials are needed to confirm these findings. Results of a recently completed clinical trial on secondary prophylaxis with rFVIIa in frequently bleeding haemophilia patients with inhibitors are expected in late 2006...
  58. ncbi Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma
    Birgitte Scharling
    Novo Nordisk A S, Bagsvaerd, Denmark
    Blood Coagul Fibrinolysis 18:677-84. 2007
    ....
  59. ncbi Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX
    Katherine A Lyseng-Williamson
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Pharmacoeconomics 25:1007-29. 2007
    ....
  60. doi Temporarily successful eradication therapy in acquired haemophilia with high inhibitor titer: a case report with a new protocol
    Peter Ilonczai
    University of Debrecen, Medical and Health Science Center, 2nd Department of Medicine, Division of Haemostasis, 4032, Nagyerdei krt 98 Debrecen, Hungary
    Thromb Haemost 100:149-50. 2008
  61. ncbi Surgical complications in a hemophilia patient with factor VIII inhibitor and their endovascular management
    Umar Sadat
    Cambridge Vascular Unit, Addenbrooke s Hospital, Cambridge, United Kingdom
    Vasc Endovascular Surg 42:168-72. 2008
    ..The treatment of unusual metachronous ruptured aneurysms in a patient with hemophilia A with factor VIII inhibitor is presented, and the outcomes of endovascular and open operations are discussed...
  62. ncbi Hemophilia care in the 21st century
    Christine L Kempton
    Division of Hematology Oncology at the University of North Carolina, Chapell Hill, NC 27599 7035, USA
    Clin Adv Hematol Oncol 2:733-40. 2004
  63. ncbi Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood
    Grigoris T Gerotziafas
    Service d Hematologie Biologique, Hopital Hotel Dieu de Paris, 1 Place du Parvis Notre Dame, 75181, Paris, Cedex 04, France
    Thromb Haemost 91:531-7. 2004
    ..The potential clinical use of rFVIIa as haemostatic treatment of major bleedings related to fondaparinux has to be evaluated...
  64. ncbi Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX
    G E Tjønnfjord
    Section of Hematology, Medical Department, Rikshospitalet University Hospital, Oslo, Norway
    Haemophilia 10:174-8. 2004
    ..A 69-year-old man who suffered a myocardial infarction the third postoperative day following sigmoidectomy was managed safely with opiate analgesia, nitrates and diuretics, and the continued use of FEIBA(R)...
  65. ncbi Excision of pseudotumour in a patient with haemophilia A and inhibitor managed with recombinant factor VIIa
    H Takedani
    Department of Orthopaedic Surgery, National Sanatorium Fukui Hospital, Kiyama, Mikata cho, Mikata gun, Fukui, Japan
    Haemophilia 10:179-82. 2004
    ..Although a spontaneous haemorrhage was observed on postoperative day 8, haemostasis was achieved by reducing the dosage interval. No adverse event occurred during the course of treatment...
  66. ncbi Evaluation of the impact of information about treatment-related risks in patients receiving blood-derived or recombinant medications
    D Magli-Barioz
    Haemophilia Treatment Centre, Cochin Hospital, Paris, France
    Haemophilia 10:572-81. 2004
    ..We think that this information must be appropriate for patients and be communicated orally within the patient-physician relationship...
  67. ncbi Recombinant factor VIIa: a general hemostatic agent? Yes
    H R Roberts
    Division of Hematology Oncology, Department of Medicine and The Carolina Cardiovascular Biology Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7035, USA
    J Thromb Haemost 2:1691-4. 2004
  68. ncbi Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety
    Stefan Lethagen
    Department for Coagulation Disorders, University of Lund, University Hospital, Malmo, Sweden
    Semin Thromb Hemost 29:101-6. 2003
    ..In general, only the mildest hemophilia A patients respond sufficiently. Optimal hemostatic effect is achieved with a dosage of 0.3 microg/kg given intravenously. An intranasal desmopressin spray is suitable for the home treatment...
  69. pmc Warfarin reversal
    J P Hanley
    Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne UK
    J Clin Pathol 57:1132-9. 2004
    ..This review discusses the current approaches to warfarin reversal in clinical practice. The development of a uniform approach to warfarin reversal in the Northern Region is described...
  70. ncbi Recombinant factor VIIa (Novoseven) restores deficient coagulation: experience from an ex vivo model
    A M Galan
    Servicio de Hemoterapia Hemostasia, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Semin Hematol 38:10-4. 2001
    ..This could improve hemostasis in patients with hemophilia A and inhibitors, and in patients treated with oral anticoagulants...
  71. ncbi Recombinant factor VIIa: a general hemostatic agent? Not yet
    M Levi
    Department of Internal Medicine and Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Thromb Haemost 2:1695-7. 2004
  72. ncbi Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa
    B Sørensen
    Center for Hemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby Sygehus, Denmark
    J Thromb Haemost 2:102-10. 2004
    ..The method appears useful for assessment of the hemostatic capacity and it seems a promising tool for evaluation of the individual response to rFVIIa or APCC before and during in vivo administration...
  73. ncbi Inhibitor treatment: state of the art
    Amy Shapiro
    Dis Mon 49:22-38. 2003
    ....
  74. ncbi Two subpopulations of thrombin-activated platelets differ in their binding of the components of the intrinsic factor X-activating complex
    M A Panteleev
    National Research Center for Hematology, Russian Academy of Medical Sciences, Moscow, Russia
    J Thromb Haemost 3:2545-53. 2005
    ....
  75. ncbi Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A
    T Lisman
    Thrombosis and Hemostasis Laboratory, G03 647, Department of Hematology, University Medical Center, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    J Thromb Haemost 1:2175-8. 2003
    ..Recently, rFVIIa variants with a specific enhancement of the tissue factor (TF)-independent proteolytic activity have been described...
  76. ncbi Prevalent misconceptions about acute retinal vascular occlusive disorders
    Sohan Singh Hayreh
    Department of Ophthalmology and Visual Sciences, College of Medicine, University of Iowa, Iowa City, IA 55242 1091, USA
    Prog Retin Eye Res 24:493-519. 2005
    ..e. with aspirin and/or anti-coagulants; (xv) fibrinolytic agents can dissolve an organized thrombus in the CRV; (xvi) it is beneficial to lower blood ..
  77. ncbi Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    J Fareed
    Hemostasis and Thrombosis Research Laboratoires, Loyola University Medical Center, Maywood, IL, USA
    Int Angiol 27:176-92. 2008
    ..Heparins, warfarin and aspirin will continue to play a major role in the management of thrombotic and cardiovascular disorders for years to come...
  78. ncbi Effect of pH on the gelation properties of skim milk gels made from plant coagulants and chymosin
    C L C Esteves
    Department of Food Science, University of Wisconsin Madison, 1605 Linden Drive, Madison WI 53706, USA
    J Dairy Sci 86:2558-67. 2003
    ..small amplitude oscillatory rheology as well as a large deformation (yield) test for gels induced by the plant coagulants, Cynara cardunculus L. and Cynara humilis L., and chymosin...
  79. pmc Development and application of different methods for the detection of Toxoplasma gondii in water
    Christina Kourenti
    Institute for Medical Parasitology, Medical Faculty, University of Bonn, 53127 Bonn, Germany
    Appl Environ Microbiol 69:102-6. 2003
    ..recovered either by centrifugation of the contaminated samples at various g values or by flocculation with two coagulants, Fe(2)(SO(4))(3) and Al(2)(SO(4))(3)...
  80. ncbi Evaluation of waste activated sludge as a coagulant aid for the treatment of industrial wastewater containing mixed surfactants
    Tongchai Sriwiriyarat
    Department of Chemical Engineering, Faculty of Engineering, Burapha University, Chonburi, Thailand
    J Environ Sci Health A Tox Hazard Subst Environ Eng 44:507-14. 2009
    ..The effective dosages of both coagulants with and without the WAS additions were determined in this study...
  81. ncbi Study on the hydrolysis/precipitation behavior of Keggin Al13 and Al30 polymers in polyaluminum solutions
    Zhaoyang Chen
    Key Laboratory of Renewable Energy and Gas Hydrate, CAS, Guangzhou Institute of Energy Conversion, Chinese Academy of Sciences, Guangzhou, China
    J Environ Manage 90:2831-40. 2009
    ..The Zeta potential of coagulant hydrolysis precipitates decreased with the increase in pH for the three coagulants. The iso-electric points of the freshly formed precipitates for AlCl(3), PAC(Al13) and PAC(Al30) were 7.3, 9...
  82. ncbi Polar nitrogen compounds and their behaviour in the drinking water treatment process
    J Pietsch
    DVGW TZW Karlsruhe, Aussenstelle Dresden, Germany
    Water Res 35:3537-44. 2001
    ..Flocculation tests using iron salts as well as aluminium salts as coagulants showed very low removal rates for the amines...
  83. ncbi The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine
    Paul Elliott
    Department of Epidemiology and Public Health, Faculty of Medicine, Imperial College London, St Mary s Campus, Norfolk Place, London W2 1PG, UK
    Int J Epidemiol 37:234-44. 2008
    ..The biological samples that are collected and how they are processed and stored will have a major impact on the future scientific usefulness of the UK Biobank resource...
  84. ncbi Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants
    Zohar Levi
    Department of Gastroenterology, Rabin Medical Center, Beilinson Campus, Petach Tikvah, Israel
    Am J Gastroenterol 104:933-8. 2009
    ..We evaluated the effect of the use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDS), and anticoagulants on the performance of immunochemical fecal occult blood test (I-FOBT)...
  85. ncbi Environmental concerns of desalinating seawater using reverse osmosis
    Gurudeo Anand Tularam
    Griffith School of Environmental, Griffith University, Australia
    J Environ Monit 9:805-13. 2007
    ..This involves treating for pH, coagulants, Cl, Cu, organics, CO(2), H(2)S and hypoxia...
  86. ncbi Complementary effects of Mediterranean diet and moderate red wine intake on haemostatic cardiovascular risk factors
    D Mezzano
    Department of Hematology Oncology, School of Medicine, Catholic University of Chile, Santiago, Chile
    Eur J Clin Nutr 55:444-51. 2001
    ..Also, to test if red wine supplementation modifies HCVRF, independent of diet...
  87. ncbi An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis
    Armando Tripodi
    Department of Internal Medicine and Medical Specialties, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy
    Gastroenterology 137:2105-11. 2009
    ..We investigated whether plasma from cirrhotic patients has an imbalance of pro- vs anti-coagulation factors...
  88. ncbi The application of novel coagulant reagent (polyaluminium silicate chloride) for the post-treatment of landfill leachates
    N D Tzoupanos
    Division of Chemical Technology, Department of Chemistry, Aristotle University of Thessaloniki, Thessaloniki GR 54124, Greece
    Chemosphere 73:729-36. 2008
    ..e. the composite coagulant polyaluminium silicate chloride. Composite coagulants with different Al to Si molar ratio and different preparation methods were tested...
  89. ncbi Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis
    J Eileen Bird
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    Thromb Res 123:146-58. 2008
    ..The goal of the current study was to benchmark representative marketed drugs in thrombosis and hemostasis models in guinea pigs...
  90. ncbi Removal of THM precursors by coagulation or ion exchange
    Brian Bolto
    CSIRO Molecular Science, Clayton South, Victoria, Australia
    Water Res 36:5066-73. 2002
    ..Unequivocal evidence was obtained that coagulants remove material that is not adsorbed by resins, and vice versa...
  91. pmc Against the motion: Lasers are superfluous for the surgical management of benign prostatic hyperplasia in the developing world
    Anil Varshney
    RG Stone Urology and Laparoscopy Hospital, F 12, East of Kailash, New Delhi 110 065, India
    Indian J Urol 25:409-12. 2009
    ..Due to superior hemostatic capabilities and non interference lasers can be used in patients on anti coagulants, cardiac pacemaker...
  92. ncbi Characterisation of titanium tetrachloride and titanium sulfate flocculation in wastewater treatment
    Y Okour
    Faculty of Engineering and IT, University of Technology Sydney, Sydney, NSW 2007, Australia
    Water Sci Technol 59:2463-73. 2009
    ..The two coagulants were compared with the commonly used coagulants such as ferric chloride (FeCl(3)) and aluminium sulfate (Al(2)(..
  93. ncbi Transfer and transport of aluminum in filtration unit
    Wang Wen-dong
    Department of Environmental Science and Engineering, Tsinghua University, Beijing 100084, China
    J Environ Sci (China) 19:897-901. 2007
    Aluminum salt coagulants were used prevalently in various water works...
  94. ncbi Toward understanding the efficacy and mechanism of Opuntia spp. as a natural coagulant for potential application in water treatment
    Sarah M Miller
    Department of Chemical Engineering, Yale University, New Haven, Connecticut 06520, USA
    Environ Sci Technol 42:4274-9. 2008
    ..suggest that these natural coagulants operate through different mechanisms. It is suggested that Opuntia spp...
  95. ncbi Cost effective and advanced phosphorus removal in membrane bioreactors for a decentralised wastewater technology
    R Gnirss
    Berliner Wasserbetriebe, Germany
    Water Sci Technol 47:133-9. 2003
    ..Current practice of P-removal in MBRs is the addition of coagulants in a co-precipitation mode...
  96. ncbi Virus inactivation in aluminum and polyaluminum coagulation
    Yoshihiko Matsui
    Department of Civil Engineering, Gifu University, 1 1 Yanagido, Gifu 501 1193, Japan
    Environ Sci Technol 37:5175-80. 2003
    Inorganic aluminum salts, such as aluminum sulfate, are coagulants that cause small particles, such as bacteria and viruses as well as inorganic particles, to destabilize and combine into larger aggregates...
  97. ncbi Is it necessary to stop antiplatelet agents before a native renal biopsy?
    Bruce Mackinnon
    Renal Unit, Glasgow Royal Infirmary, Glasgow, United Kingdom
    Nephrol Dial Transplant 23:3566-70. 2008
    ..A secondary aim, therefore, was to compare complication rates from this cohort with those reported in the literature where screening for prolonged bleeding time is standard practice...
  98. ncbi Physical properties and biocompatibility of cellulose/soy protein isolate membranes coagulated from acetic aqueous solution
    Li Hua Luo
    Research Center for Medical and Structural Biology, School of Basic Medical Science, Wuhan University, Wuhan, China
    J Biomater Sci Polym Ed 19:479-96. 2008
    ..The effects of SPI content (W(SPI)) and the coagulants on the structure and properties of the membranes were investigated. The membranes exhibited porous structure...
  99. ncbi [Relationship among coagulation effect of Al-based coagulant, content and speciation of residual aluminum]
    Zhong Lian Yang
    Shandong Key Laboratory of Water Pollution Control and Resource Reuse, School of Environmental Science and Engineering, Shandong University, Ji nan 250100, China
    Huan Jing Ke Xue 31:1542-7. 2010
    ..It is intended to discuss the relationship among coagulation effect of Al-based coagulants in humic acid-kaolin simulated water and content and speciation of residual aluminum...
  100. ncbi Effect of pH on the coagulation performance of Al-based coagulants and residual aluminum speciation during the treatment of humic acid-kaolin synthetic water
    Zhong Lian Yang
    Shandong Key Laboratory of Water Pollution Control and Resource Reuse, School of Environmental Science and Engineering, Shandong University, Ji nan 250100, China
    J Hazard Mater 178:596-603. 2010
    ..0 while PAC showed stable HA and UV(254) removal capacity with broader pH variation (5.0-8.0). For the three coagulants, majority of residual aluminum existed in the form of total dissolved Al (60-80%), which existed mostly in ..
  101. ncbi Innovative physico-chemical treatment of wastewater incorporating Moringa oleifera seed coagulant
    Hitendra Bhuptawat
    Centre for Environmental Science and Engineering, Indian Institute of Technology Bombay, Powai, Mumbai 400076, India
    J Hazard Mater 142:477-82. 2007
    ..seeds contain a high quality edible oil (up to 40% by weight) and water soluble proteins that act as effective coagulants for water and wastewater treatment...

Research Grants33

  1. Microbial Diversity in Mechanisms of Disulfide Bond Formation and Reduction
    Dana Boyd; Fiscal Year: 2013
    ..for their activity as candidates for development as potential antibiotics against tuberculosis and as anti-coagulants. (Human VKOR is a component of the blood coagulation pathway...
  2. Plasmon-Controlled Fluorescence and Cardiac Markers
    Joseph R Lakowicz; Fiscal Year: 2013
    ..Rapid diagnosis is essential either to initiate rapid treatment with anti-coagulants or to determine the symptoms are non-threatening...
  3. Multiscale, Multiphysics Model of Thrombus Biomechanics in Aortic Dissection
    George Karniadakis; Fiscal Year: 2013
    ..In addition, our model will be designed to simulate the potential benefits of two anti-coagulants in terms of the time(s) of delivery...
  4. Atherosclerotic Risk and Response to Exercise Intervention in HIV+ Children
    Tracie L Miller; Fiscal Year: 2010
    ..study evaluating vascular inflammatory pathways (biomarkers of inflammation, endothelial dysfunction, pro-coagulants and metabolic dysfunction) and vascular dysfunction (through flow-mediated vasodilation studies [FMD] and ..
  5. Development of biomimetic oligomers as anticoagulant antagonists
    Richard W Scott; Fiscal Year: 2010
    ..RELEVANCE: Low molecular weight heparins (LMWHs) and the pentasaccharide, fondaparinux, are widely used anti-coagulants employed in a number of clinical and surgical applications...
  6. Protein-cell assemblies as tissue-mimics
    Xiaoyi Wu; Fiscal Year: 2010
    ..Specific Aim 1. Coaxially electrospin recombinant silk-elastin-like proteins (SELPs) and crosslinking agents or coagulants into a robust fibrous scaffold without post-electrospinning treatments...
  7. Novel Reagents to Bypass Limitations of Existing Coagulation Assays
    Stephen Burgess; Fiscal Year: 2009
    ..These agents are referred to as Lupus anti-coagulants, and their presence can result in misdiagnosis, which can greatly complicate patient care...
  8. Development of biomimetic oligomers as anti-coagulant antagonists
    Richard Scott; Fiscal Year: 2007
    ..by applicant): Unfractionated heparin (UFH) and the low molecular weight heparins (LMWHs) are widely used anti-coagulants employed in a number of clinical and surgical applications...
  9. Targeting Caveolae in Breast Tumors
    Jan Schnitzer; Fiscal Year: 2006
    ..marker expression on the tumor endothelium indicate that vascular targeting with immunotoxins and immuno-coagulants causes significant tumor regression...
  10. ANTI-THROMBOGENIC COATING FOR MEDICAL DEVICES
    SCOTT ROSEBROUGH; Fiscal Year: 2003
    ..The clinical means to prevent thrombosis still requires the co-administration of anti-coagulants, predominantly heparin...
  11. Is Stroke a Late Effect of Chemotherapy?
    Ann Geiger; Fiscal Year: 2006
    ..cancer site, stage at diagnosis, year of diagnosis, and dispensed medications for hypertension, diabetes, anti-coagulants and tamoxifen (for breast cancer only)...
  12. A Bioactive Polymer Designed for Cardiac Assist Devices
    Robert Stewart; Fiscal Year: 2003
    ..The polymer developed here will provide a slow, in situ release or anti-coagulants at the blood: surface interface, thereby changing the local coagulation properties...
  13. A NEW SOURCE OF HYALURONIDASE AND ANTI-COAGULANTS
    GUNTHER STENT; Fiscal Year: 1980
    ..ghilianii to provide enough material for the isolation and chemical characterization of the fibrinolysin, and possibly, begin the testing of its in vivo effects...
  14. Pathophysiology of anti-B2GPI Antibodies in APS
    ALISA WOLBERG; Fiscal Year: 2008
    ..It is expected that these proposed studies will contribute to a fundamental understanding of pathogenic mechanisms for thrombosis in APS and lead to future investigations addressing therapeutic interventions in APS. ..
  15. CELL MEDIATED HEMOSTASIS
    Harold Roberts; Fiscal Year: 2004
    ....
  16. Factor XIII Activation and Substrate Specificity
    Muriel C Maurer; Fiscal Year: 2010
    ..Research will focus on understanding how Factor XIII is turned on and how it selects its targets. Studies may lead to novel medical strategies to control the actions of Factor XIII and the resultant clot architecture. ..
  17. CONFERENCE ON HIV PATHOGENESIS
    Michael Lederman; Fiscal Year: 2005
    ....
  18. Statistical Methods to Study the Epidemiology of HIV & Other Disease
    Nicholas P Jewell; Fiscal Year: 2010
    ....
  19. Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in children
    Guy Young; Fiscal Year: 2009
    ..More modern therapies are available but have not been systematically tested in children. This study will determine whether one such medication, bivalirudin is a safer and more effective alterative. ..
  20. Immune Mechanisms and HIV Disease Pathogenesis
    Michael Lederman; Fiscal Year: 2004
    ..The proposal's specific request is for support to increase participation in the Conference by female and/or minority researchers and students. ..
  21. 2007 Case CFAR Annual Spring Conference
    Michael Lederman; Fiscal Year: 2007
    ..The Case CFAR is proactive in its efforts to ensure inclusion of minority and female researchers in[unreadable] all aspects of Conference planning and attendance. ..
  22. Biomarker Profiles in the Diagnosis/Prognosis of ARDS
    Lorraine Ware; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  23. Pathophysiologies Involving Hemostasis-related Genes
    Francis Castellino; Fiscal Year: 2008
    ..abstract_text> ..
  24. Alveolar Epithelium in Acute Lung Injury
    Lorraine Ware; Fiscal Year: 2005
    ..Combined with a compelling research project, the training will -provide the skills necessary for a successful career in biomedical research. ..
  25. Pathophysiology of thiamine-responsive anemia syndrome
    Ellis Neufeld; Fiscal Year: 2006
    ....
  26. INITIATION AND REGULATION OF BLOOD COAGULATION
    VIJAYA MOHAN RAO LELLA; Fiscal Year: 2010
    ..abstract_text> ..
  27. FONDAPARINUM IN CHILDREN WITH THROMBOSIS
    Guy Young; Fiscal Year: 2007
    ..Pharmacokinetic analyses as well as safety and efficacy determinations will be made which will provide valuable information on this new anticoagulant for pediatric patients. [unreadable] [unreadable]..
  28. Case CFAR Meeting: HIV Pathogenesis
    Michael Lederman; Fiscal Year: 2006
    ..Presentation sessions will be Cellular Restrictions Factors; Latency; Protection from HIV Infection; Immune Pathogenesis; and Vaccines. ..
  29. Topical Immune modulatory strategies to prevent HIV transmission
    Michael Lederman; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  30. NATURAL HISTORY AND TREATMENT OUTCOME IN BRAIN AVM
    JP MOHR; Fiscal Year: 2005
    ..The results are improving the prediction for short- and long-term outcome for embolization and surgery. ..
  31. WARFARIN ANTIPLATELET RECURRENT STROKE STUDY
    J Mohr; Fiscal Year: 2001
    ..An emergency notification system helps maintain patient safety. Through 24-Oct-1996 1603 patients have been recruited from 49 participating centers toward the 1,920 patient sample size. ..
  32. Statistical Techniques for Complex Environmental Epidemiological Studies
    Nicholas P Jewell; Fiscal Year: 2010
    ....
  33. ANNEXIN II & PLASMIN MEDIATED HIGH GRADE GLIOMA INVASION
    Suchitra Acharya; Fiscal Year: 2002
    ..Dr. Hajjar is also very accessible for individual weekly meetings when the need arises. T h i s environment will provide excellent training for a developing physician-researcher. ..